Navigation Links
Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
Date:5/24/2011

n CS, Kremers HM et al. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum. 2010;62(6):1576-1582.
  • Martinon F, Glimcher LH. Gout: new insights into an old disease. J Clin Invest. 2006; 116(8):2073-5.
  • Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006; 440(7081):237-41.
  • Mandell BF. Clinical manifestations of hyperuricemia and gout. Cleve Clin J Med. 2008; 75(5):S5-8.
  • Busso N, So A. Mechanisms of inflammation in gout. Arthritis Res Ther. 2010; 12:206-13.
  • So A, De Meulemeester M, Pikhlak EA, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis. Arthritis Rheum. 2010 October; 62(10):3064-76.
  • Terkeltaub R, Edwards NL. Gout: Diagnosis and Management of Gouty Arthritis and Hyperuricemia. 1st ed. West Islip, NY: Professional Communications, Inc; 2010.
  • Schlesinger N, Dalbeth N, Perez-Ruiz F. Gout—what are the treatment options? Expert Opin Pharmacother. 2009;10:1319-28.
  • Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology. 2007;46:1372-4.
  • Riedel AA, Nelson M, Wallace K, Joseph-Ridge N, Cleary M, Fam AG. Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol. 2004 Dec; 10(6):308-14.
  • So A, Alten R, Bardin T, et al. A controlled trial of canakinumab vs triamcinolone acetonide in acute gouty arthritis patients: results of the Beta-RELIEVED study (REsponse in acute fLare and In prEVEntion of episoDes of re-flare in gout). Oral presentation (OP0108) at: The 2011 Annual European Congress of The European League Against Rheumatism; 2011
    '/>"/>

  • SOURCE Novartis Pharmaceuticals Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
    2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
    3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
    4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
    5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
    6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
    7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
    8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
    9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
    10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
    11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ... the District of New Jersey ... against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... that U.S. Patent No. 6,765,117 is both valid and ... its generic product until the expiration of that patent ...
    (Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will present a ... and New Zealand Forensic Science Society,s 22 nd ... Adelaide, Australia .  Forensic Scientists ... advancements that hyperspectral imaging can bring to examination ... , Director of Product Development at ChemImage, will ...
    (Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, ... (OTCQB: DMPI) ("DelMar" "the Company") today announced the filing ... Company recently changed its fiscal year end to June ... its common stock on a national securities exchange in ... as filed with the United States Securities Exchange Commission ...
    Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
    (Date:8/29/2014)... (PRWEB) August 29, 2014 A team ... wellness solutions, is on its way to the 2014 ... San Diego Convention Center to exhibit and demonstrate a ... in high-noise industrial environments. Etymotic’s safety earphones and high-definition ... technology devices at the show. , The company’s ...
    (Date:8/29/2014)... City, Calif. (PRWEB) August 29, 2014 ... and customer service solutions, today announced that LiveOps has ... Muscular Dystrophy Association's (MDA) Show of Strength Telethon for ... entertainment event raises money and awareness to support MDA’s ... dystrophy, an aggressive and sometimes fatal muscle disease. This ...
    (Date:8/29/2014)... 29, 2014 (HealthDay News) -- Prostate cancer patients lacking ... decisions. This can lead to worse quality of care ... included 70 men, with a median age of 63. ... Poor understanding of the disease was associated with greater ... that the treatment would be effective, the study found. ...
    (Date:8/29/2014)... Medicine have identified one way the Ebola virus dodges ... lead to new therapies, in research results ... . , In work performed at Beamline 19ID at ... a detailed map of how a non-pathogenic Ebola protein, ... molecules in and out of the cell nucleus. , ...
    (Date:8/29/2014)... Pittsburgh, PA (PRWEB) August 29, 2014 ... inventor from Harrisburg, Pa., had to have breast reconstruction. ... to be sub-par, so she decided that there needed ... a better look for a woman or man who ... visible, as well as promotes confidence and peace of ...
    Breaking Medicine News(10 mins):Health News:Etymotic’s Safe Listening Earphones and Earplugs Headed For The 2014 NSC Safety Expo 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 3Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 4Health News:Faced With Prostate Cancer, It Helps to Know the Enemy 2
    ... function a serious concern, researchers say , TUESDAY, Jan. 26 (HealthDay ... with the virus that causes AIDS, new research suggests. , It,s ... -- or both -- are contributing to the aging. But one ... the same as in those of uninfected people who are 15 ...
    ... Clinicians use Epocrates ... ... -- Epocrates, Inc., a leading developer of mobile clinical and decision support software, ... 2009. The market demand and clinician need for its mobile and online solutions among large ...
    ... progression, study finds , TUESDAY, Jan. 26 (HealthDay ... drug pazopanib (Votrient) slowed their disease progression by 54 ... 3 study included 233 patients with previously untreated kidney ... locally advanced or had spread, and 202 patients with ...
    ... ... to push fans to reach their fitness goals with the 5-Hour Energy Workout Challenge. , ... Farmington Hills, MI (PRWEB) January 26, 2010 -- ... fitness goals with the 5-Hour Energy Workout Challenge ., , , , ,The Workout Challenge ...
    ... , SYRACUSE, N.Y. , Jan. 26 ... recent earthquake in Haiti , Aspen Dental Management, Inc. (ADMI) ... ," a voluntary program that gives Aspen Dental employees the option ... Red Cross for Haiti relief and development. Aspen Dental ...
    ... As the debates about "eat this -- not that" ... the record straight about what sweetens most of the non-diet beverages ... Syrup 55 (HFCS), not sugar (sucrose).   , In hundreds of ... sugar is misidentified as a prominent soda sweetener. Terms like "sugary ...
    Cached Medicine News:Health News:Premature Aging of the Brain Seen in HIV Patients 2Health News:Health Systems, Hospitals and Universities Nationwide Chose Epocrates in 2009 for Trusted Point-of-Care Clinical Information 2Health News:Health Systems, Hospitals and Universities Nationwide Chose Epocrates in 2009 for Trusted Point-of-Care Clinical Information 3Health News:New Drug Slows Advanced Kidney Cancer 2Health News:The 5-Hour Energy Workout Challenge 2Health News:The 5-Hour Energy Workout Challenge 3Health News:Aspen Dental Employees to Give 'An Hour for Haiti' 2Health News:Sugar Association Seeks to Set the Record Straight on 'Sugar-Sweetened Beverage' Terminology 2
    IDS Rapid One, a microbial identification system....
    IDS Rapid NF Plus, a microbial identification system....
    Versatrek 240 is versatile as four tests can be performed on one platform such as blood culture, sterile body fluids, mycobacteria and mycobacteria susceptibility testing. This model comes equipped w...
    BD Phoenix is an automated microbiology system used for identification and susceptibility testing....
    Medicine Products: